This Briefing presents the results from the CIRS annual analysis of New Active Substance (NAS) approvals by six major regulatory agencies: the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), the Japan Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Swissmedic and the Australian Therapeutic Goods Administration (TGA). The analysis focuses on 2019 as well as looking back at 2010-2019.
Although median approval times can be a marker of agency performance and the time it takes to make medicines available to patients, other factors need to be taken into account. This Briefing focuses on two such factors, namely facilitated regulatory pathways (FRPs) and internationalisation based on company strategy to ensure timely availability of medicines globally. We have also highlighted which regulatory trends COVID-19 might impact in the coming year.
The NAS list associated with this Briefing is available to download here.
If you have any questions or comments on this Briefing, please don’t hesitate to get in touch with Céline Rodier: crodier@cirsci.org
